within Pharmacolibrary.Drugs.ATC.D;

model D11AH09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.31666666666666665,
    adminDuration  = 600,
    adminMass      = 0.025,
    adminCount     = 1,
    Vd             = 0.072,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.024,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ruxolitinib is an oral Janus kinase (JAK1 and JAK2) inhibitor approved for the treatment of myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It is used to modulate overactive JAK signaling associated with hematological malignancies and is widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics were reported in healthy adult subjects after oral administration; data represent averages from publications and FDA documentation.</p><h4>References</h4><ol><li>T Y J Appeldoorn, T H Oude Munnink, L M Morsink, M N Lub-de Hooge, D J Touw,Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.,Clinical pharmacokinetics,2023<a href='https://pubmed.ncbi.nlm.nih.gov/37000342/'>https://pubmed.ncbi.nlm.nih.gov/37000342/</a></li><li>Eleanor Cook, Min Dong, Samuel C C Chiang, David Luedeke, Kelly E Lake, Colin Hoerth, Marisa Deavy, Kenneth D R Setchell, Junfang Zhao, Nieko Punt, Thomas Galletta, Ashley Teusink-Cross, Stella M Davies, Rebecca A Marsh, Parinda Mehta, Pooja Khandelwal,Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease.,Transplantation and cellular therapy,2024<a href='https://pubmed.ncbi.nlm.nih.gov/38401793/'>https://pubmed.ncbi.nlm.nih.gov/38401793/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D11AH09;
